ADMA

ADMA Biologics Inc

9.23 USD

Last updated Sep 12, 05:00 UTC

Yesterday HIGH

$9.5

Yesterday LOW

$9.33

52w HIGH

$20.46

52w LOW

$7.21

EPS

0.16

PE

57.69

Next Earnings

Nov 4, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

ADMA Biologics Inc stock is down -1.91% since 30 days ago. The next earnings date is Nov 4, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

05 Aug 18:05	21 Aug, 2026	9.00	CALL	2997	477
06 Aug 16:34	21 Jan, 2028	10.00	PUT	100	257
06 Aug 16:34	21 Jan, 2028	10.00	PUT	99	257
06 Aug 17:08	21 Jan, 2028	10.00	CALL	124	1792
06 Aug 17:22	21 Jan, 2028	10.00	CALL	200	1792
06 Aug 17:28	21 Jan, 2028	10.00	CALL	200	1792
06 Aug 17:29	21 Jan, 2028	10.00	CALL	99	1792
06 Aug 17:36	21 Jan, 2028	10.00	CALL	101	1792
13 Aug 14:48	21 Aug, 2026	10.00	PUT	1000	143
19 Aug 13:36	21 Jan, 2028	8.00	CALL	100	276

Advanced Data Unlock

Avi Kapoor

Thu May 7, 2026

Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket

Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.
Benzinga Newsdesk

Wed May 6, 2026

ADMA Biologics Withdraws Long-Term Guidance To Reflect Evolving U.S. Plasma Products And IG Market Competitive Dynamics
Benzinga Insights

Wed May 6, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights

Wed May 6, 2026

Earnings Scheduled For May 6, 2026
Benzinga Newsdesk

Wed May 6, 2026

ADMA Biologics shares are trading lower after the company reported worse-than-expected Q1 financial results and issued FY26 sales guidance below estimates.
Benzinga Newsdesk

Wed May 6, 2026

ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est

ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.
Benzinga Newsdesk

Wed May 6, 2026

ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14 per share from the
Benzinga Newsdesk

Mon May 4, 2026

ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV

The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.Additionally, the approval provides for a revision of ASCENIV's prescribing information to
Benzinga Newsdesk

Tue Apr 21, 2026

Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.
Avi Kapoor

Mon Apr 13, 2026

Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.

MLTX $12.52 USD

ASML $1,699.24 USD

DELL $566.53 USD

HIMS $27.50 USD

INOD $53.21 USD

RVMD $203.83 USD